Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 10;16(5):743-745.
doi: 10.1021/acsmedchemlett.5c00180. eCollection 2025 May 8.

Reducing Cardiovascular Side Effects of DMT Using Beta-Blockers

Robert B Kargbo  1
Affiliations
Editorial

Reducing Cardiovascular Side Effects of DMT Using Beta-Blockers

Robert B Kargbo. ACS Med Chem Lett. .

Abstract

DMT induces rapid antidepressant effects, but acute sympathomimetic side effects, particularly hypertension and tachycardia, limit its use. This study describes coformulations with short-acting beta-blockers or nitrates, matched to DMT's pharmacokinetics, to mitigate peripheral cardiovascular risks without compromising central therapeutic action, facilitating safer psychedelic therapy in vulnerable populations.

PubMed Disclaimer

Conflict of interest statement

The author declares no competing financial interest.

Similar articles

See all similar articles

References

    1. van der Heijden K. V.; Otto M. E.; Schoones J. W.; van Esdonk M. J.; Borghans L. G. J. M.; van Hasselt J. G. C.; van Gerven J. M. A.; Jacobs G. Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Posthoc Analysis. Clin. Pharmacokinet. 2025, 64, 215–227. 10.1007/s40262-024-01450-8. - DOI - PMC - PubMed
    1. Schimmelpfennig J.; Jankowiak-Siuda K. Exploring DMT: Endogenous Role and Therapeutic Potential. Neuropharmacology 2025, 268, 110314.10.1016/j.neuropharm.2025.110314. - DOI - PubMed
    1. Halman A.; Conyers R.; Moore C.; Khatri D.; Sarris J.; Perkins D. Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy. Clin. Pharmacol. Ther. 2025, 117, 106–115. 10.1002/cpt.3459. - DOI - PMC - PubMed
    1. Archer C.; Wiles N.; Kessler D.; Turner K.; Caldwell D. M. Beta-Blockers for the Treatment of Anxiety Disorders: A Systematic Review and Meta-analysis. J. Affect. Disord. 2025, 368, 90–99. 10.1016/j.jad.2024.09.068. - DOI - PubMed
    1. Eddin L. E.; Preyra R.; Ahmadi F.; Jafari A.; Omrani M. A.; Muanda F. T. β-Blockers and Risk of Neuropsychiatric Disorders: A Systematic Review and Meta-analysis. Br. J. Clin. Pharmacol. 2025, 91, 325–337. 10.1111/bcp.16361. - DOI - PMC - PubMed

Publication types

LinkOut - more resources